‘Safe route' or ‘sushi route' − 2 strategies to turn yuck to yum and convince people to eat unusual foods
What will the diets of the future look like? The answer depends in part on what foods Westerners can be persuaded to eat.
These consumers are increasingly being told their diets need to change. Current eating habits are unsustainable, and the global demand for meat is growing.
Recent years have seen increased interest and investment in what are called alternative proteins – products that can replace typical meats with more sustainable alternatives. One option is cultivated, or cultured, meat and seafood: muscle tissue grown in labs in bioreactors, using animal stem cells. Another approach involves replacing standard meat with such options as insects or plant-based imitation meats. All of these products promise a more sustainable alternative to factory-farmed meat. The question is, will consumers accept them?
I'm a philosopher who studies food and disgust, and I'm interested in how people react to new foods such as lab-grown meat, bugs and other so-called alternative proteins. Disgust and food neophobia – a fear of new foods – are often cited as obstacles to adopting new, more sustainable food choices, but I believe that recent history offers a more complicated picture. Past shifts in food habits suggest there are two paths to the adoption of new foods: One relies on familiarity and safety, the other on novelty and excitement.
Disgust is a strong feeling of revulsion in response to objects perceived to be contaminating, polluting or unclean. Scientists believe that it evolved to protect human beings from invisible contaminants such as pathogens and parasites. Some causes of disgust are widely shared, such as feces or vomit. Others, including foods, are more culturally variable.
So it's not surprising that self-reported willingness to eat insects varies across nationalities. Insects have been an important part of traditional diets of cultures around the world for thousands of years, including the ancient Greeks.
Many articles about the possibility of introducing insects to Western or American diners have emphasized the challenges posed by neophobia and 'the yuck factor.' People won't accept these new foods, the thinking goes, because they're too different or even downright disgusting.
If that's right, then the best approach to win space on the plate for new foods might be to try to make them seem similar to familiar menu items.
During World War II, the United States government wanted to redirect its limited meat supply to troops on the front lines. So it needed to convince home cooks to give up their steaks, chops and roasts in favor of what it called variety meats: kidneys, liver, tongue and so on.
To figure out how to shift consumer habits, a team of psychologists and anthropologists was charged with studying how food habits and preferences were formed – and how they could be changed.
The Committee on Food Habits recommended stressing these organ meats' similarity to available, familiar, existing foods. This approach – call it the 'safe route' – focuses on individual attitudes and choices. It tries to remove psychological and practical barriers to individual choice and counteracts beliefs or values that might dissuade people from adopting new foods.
As the name suggests, the safe route tries to downplay novelty, using familiar forms and tastes. For example, it would incorporate unfamiliar cuts of meats into meatloaf or meatballs or grind crickets into flour for cookies or protein bars.
But more recent history suggests something different: Foods such as sushi, offal and even lobster became desirable not despite but because of their novelty and difference.
Sushi's arrival in the postwar U.S. coincided with the rise of consumer culture. Dining out was gaining traction as a leisure activity, and people were increasingly open to new experiences as a sign of status and sophistication. Rather than appealing to the housewife preparing comfort foods, sushi gained popularity by appealing to the desire for new and exciting experiences.
By 1966, The New York Times reported that New Yorkers were dining on 'raw fish dishes, sushi and sashimi, with a gusto once reserved for corn flakes.' Now, of course, sushi is widely consumed, available even in grocery stores nationwide. In fact, the grocery chain Kroger sells more than 40 million pieces of sushi a year. Whereas the safe route suggests sneaking new foods into our diets, the sushi route suggests embracing their novelty and using that as a selling point.
Sushi is just one example of a food adopted via this route. After the turn of the millennium, a new generation of diners rediscovered offal as high-end restaurants and chefs offered 'nose to tail' dining. Rather than positioning foods like tongue and pigs' ears as familiar and comforting, a willingness to embrace the yuck factor became a sign of adventurousness, even masculinity. This framing is the exact opposite of the safe route recommended by the Committee on Food Habits.
What lessons can be drawn from these examples? For dietary shifts to last, they should be framed positively. Persuading customers that variety meats were a necessary wartime substitution worked temporarily but ultimately led to the perception that they were subpar choices. If cultivated meat and insects are pitched as necessary sacrifices, any gains they make may be temporary at best.
Instead, producers could appeal to consumers' desire for healthier, more sustainable and more exciting foods.
Cultivated meat may be 'safe-ly' marketed as nuggets and burgers, but, in principle, the options are endless: Curious consumers could sample lab-grown whale or turtle meat guilt-free, or even find out what woolly mammoth tasted like.
Ultimately, the chefs, consumers and entrepreneurs seeking to remake our food systems don't need to choose just one route. While we can grind insects into protein powders, we can also look to chefs cooking traditional cuisines that use insects to broaden our culinary horizons.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Alexandra Plakias, Hamilton College
Read more:
Plant-based meat alternatives are trying to exit the culture wars – an impossible task?
Gluten-sensitive liberals? Investigating the stereotype suggests food fads unite us all
Would you eat 'meat' from a lab? Consumers aren't necessarily sold on 'cultured meat'
Alexandra Plakias does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Leading Parkinson's Advocacy Groups Urge Strong Federal Investment in Biomedical Research
NEW YORK , June 25, 2025 /PRNewswire/ -- As Congress works to set funding levels for the National Institutes of Health, The American Parkinson Disease Association, The Michael J. Fox Foundation for Parkinson's Research and The Parkinson's Foundation call on lawmakers to ensure that a robustly funded, collaborative NIH — the essential engine of medical progress and hope for millions of Americans — is a cornerstone of the nation's budget today and in the future. Decades of dedicated scientific investigation and bipartisan support for NIH have advanced the search for next-generation treatments and brought us to the brink of transformative breakthroughs in Parkinson's care. Sustained federal investment also has contributed to recent discoveries that have unlocked brand-new understanding of shared biology across the major brain diseases, positioning the field to make even more rapid gains within the next decade. Any reorganization of NIH must be guided by these new scientific insights— with input from patients and families — to deliver mutually beneficial outcomes. It is imperative that we preserve and build on this progress by increasing investment in our national scientific enterprise through NIH on behalf of the 1 million Americans living with Parkinson's, their families and the millions more whose lives are touched by neurodegenerative disease, such as Lewy body dementia and Alzheimer's disease. This is the future our country needs and deserves. Our organizations have demonstrated the power of public-private partnership to drive scientific progress, delivering results for patients and families. We and our nationwide network of advocates will support every effort to keep this critical work moving forward through the appropriations process and in any consideration of a reorganization of NIH. We trust our nation's leaders to join us in this vital mission. About The American Parkinson Disease Association (APDA) The American Parkinson Disease Association (APDA) is a nationwide grassroots network dedicated to fighting Parkinson's disease (PD) and works tirelessly to help the approximately one million with PD in the United States live life to the fullest in the face of this chronic, neurological disorder. Founded in 1961, APDA has raised and invested more than $313 million to provide outstanding patient services and educational programs, elevate public awareness about the disease, and support research designed to unlock the mysteries of PD and ultimately put an end to this disease. About The Michael J. Fox Foundation for Parkinson's Research (MJFF) As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding $2.5 billion in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; creates a robust open- access data set and biosample library to speed scientific breakthroughs and treatment with its landmark clinical study, PPMI; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us at Facebook, Instagram and LinkedIn. About the Parkinson's Foundation The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson's community. Since 1957, the Parkinson's Foundation has invested more than $474 million in Parkinson's research and clinical care. Connect with us on Facebook, X, Instagram or call 1-800-4PD-INFO (1-800-473-4636). View original content to download multimedia: SOURCE The Michael J. Fox Foundation for Parkinson's Research; The Parkinson's Foundation; The American Parkinson Disease Association
Yahoo
35 minutes ago
- Yahoo
QT Imaging Leverages NVIDIA L40 GPU Acceleration to Power its Next-Gen Breast Imaging Reconstruction Software
– New software release delivers substantial image processing time improvements – – Faster image availability enables radiologists to review and interpret QTI breast scans more quickly, supporting earlier clinical decision-making – – Image fidelity and diagnostic accuracy improvement, in addition to the significant processing speed gains – NOVATO, Calif., June 25, 2025--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB:QTIH), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is pleased to announce its latest image reconstruction software update release, version 4.4.0, which delivers a substantial reduction in the QTscan™ image processing time, improving user throughput and overall efficiency. The software update was developed leveraging NVIDIA's L40 GPU, powered by the Ada Lovelace architecture. The U.S. FDA-cleared QTI Breast Acoustic CT™ scanner is the first non-invasive breast imaging technology that provides a true 3D image of the breast anatomy without compression, contrast administration, or harmful ionizing radiation. Despite the processing speed gains achieved via the version 4.4.0 software update, QTscan breast image fidelity and diagnostic accuracy are uncompromised, and image quality remains best-in-class, with a resolution similar to magnetic resonance imaging (MRI). Designed to meet the needs of busy breast imaging centers, the software update ensures minimal downtime and seamless integration into existing workflows. Accordingly, it enhances scalability for institutions expanding their QTI breast screening programs, ensuring consistent performance across increasing patient volumes. "This latest software release reflects direct input from radiologists and clinical partners, underscoring our commitment to continuous innovation based on real-world use," said QTI's CEO, Dr. Raluca Dinu. "Faster image availability enables radiologists to review and interpret QTI scans more quickly, supporting earlier clinical decision-making. And accelerated processing reduces wait times for results, contributing to a smoother and more reassuring patient journey." The QTI team continues to innovate by leveraging proprietary machine learning algorithms not only to accelerate image processing via the version 4.4.0 software update, but also to actively reduce scanning time — a key focus area in ongoing development. Version 4.4.0 is optimized for systems utilizing NVIDIA's L40 GPUs and remains fully backward-compatible with earlier QTI system hardware, ensuring broad accessibility through scalable, software-driven architecture. About QT Imaging Holdings, Inc. QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on QT Imaging Holdings, Inc., please visit the company's website at Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as "will," and "expect," or the negative thereof or comparable terminology, and include (without limitation) statements regarding the presentation and performance of the QT Imaging Breast Acoustic CT imaging technology, including the software update, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and "bring to market" plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading "Risk Factors" and in other sections of QT Imaging Holding's filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement. View source version on Contacts For media inquiries, please contact: Stephen Kilmer Head of Investor Direct: (646) 274-3580 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
an hour ago
- Yahoo
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
– Investigational salanersen (ION306/BIIB115) developed using novel Ionis antisense chemistry with the potential to achieve high efficacy and once-yearly dosing – – Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersen – – Biogen is engaging with regulators to advance salanersen to registrational stage studies – CARLSBAD, Calif., June 25, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA® (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and enable once-yearly dosing. Both dose levels tested, 40 mg and 80 mg, given once a year, were generally well-tolerated and led to substantial slowing of neurodegeneration, as shown by reductions in neurofilament. Exploratory clinical outcome data show clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over one year. These data will be presented today at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. The Phase 1 single ascending dose study was designed to evaluate the safety, tolerability and pharmacokinetics of salanersen. The trial consisted of two parts: Part A, a randomized and placebo-controlled segment in healthy adult male volunteers and Part B, an open-label segment in pediatric participants with SMA who previously received ZOLGENSMA® (onasemnogene abeparvovec) and had investigator-reported suboptimal clinical status. Interim results are from Part B (n=24) in individuals who received either 40 mg or 80 mg salanersen once a year. In participants with elevated baseline concentrations of neurofilament light chain (NfL), indicating ongoing neurodegeneration, initiation of salanersen led to mean reductions in NfL of 70% at 6-months which were sustained through the one-year dosing interval. "These encouraging interim results reflect the potential of Ionis' leading technology to continue to improve the lives of people living with SMA," said Holly Kordasiewicz, Ph.D., senior vice president of neurology, Ionis. "We're proud to have discovered salanersen, which builds on the foundation we established with SPINRAZA and further supports Ionis' long-standing leadership in neurology and innovative RNA-targeted medicines. We are deeply grateful to the patients, families and investigators who participated in this study and look forward to continuing to work with Biogen to support the SMA community." Salanersen was invented by Ionis using a novel antisense chemistry designed to enhance potency, stability and durability. This advanced molecular design has the potential to deliver long-term results with long-interval dosing. In addition to safety and NfL, exploratory clinical outcome data were evaluated for the subgroup of participants with at least one year of follow-up at the time of the interim analysis (n=8 participants aged 2-12 who received 40 mg of salanersen). Half (4/8) of these participants achieved new WHO motor milestones that they previously could not achieve on their own or for which they required assistance, such as walking, crawling, standing or sitting. Furthermore, these participants experienced clinically meaningful improvements in motor function from baseline to one year, including a 3.3-point (SD 4.46) mean improvement from baseline on the Hammersmith Functional Motor Scale – Expanded (HFMSE) and a 5.3-point (SD 4.75) improvement on the Revised Upper Limb Module (RULM). "Despite the remarkable therapeutic advancements in the field of SMA over the past decade, there remains critical unmet needs. Salanersen represents the next phase of Biogen's ongoing pursuit to address these needs," said Stephanie Fradette, Pharm.D., Head of the Neuromuscular Development Unit at Biogen. "We are encouraged by the available data and eager to move salanersen into the next stage of development as quickly as possible. We are deeply grateful for the trial participants and their families, investigators, and site staff." The cumulative interim data from the Phase 1 study indicate that salanersen was generally well tolerated at the 40 mg and 80 mg doses, with most adverse events (AEs) mild to moderate in severity. The most common AEs were pyrexia and upper respiratory tract infection. Biogen is currently engaging with global health authorities regarding the design of the Phase 3 studies. Ionis discovered salanersen and licensed the global development, manufacturing and commercialization rights to Biogen Inc. About Spinal Muscular Atrophy (SMA) SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages. It is characterized by a loss of motor neurons in the spinal cord and lower brain stem, resulting in progressive muscle atrophy and weakness. SMA is caused by a deficiency in the production of survival motor neuron (SMN) protein due to a damaged or missing SMN1 gene, with a spectrum of disease severity. Some individuals with SMA may never sit; some sit but never walk; and some walk but may lose that ability over time. In the absence of treatment, children with the most severe form of SMA would usually not be expected to reach their second birthday. SMA impacts approximately 1 in 10,000 live births, is a leading cause of genetic death among infants and causes a range of disability in teenagers and adults. About SPINRAZA SPINRAZA® (nusinersen) 12 mg/5 mL injection is approved in more than 71 countries to treat infants, children and adults with spinal muscular atrophy (SMA). As a foundation of care in SMA, more than 14,000 individuals have been treated with SPINRAZA worldwide. SPINRAZA is an antisense oligonucleotide (ASO) that targets the underlying cause of motor neuron loss by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body. It is administered directly into the central nervous system, where motor neurons reside, to deliver treatment where the disease starts. SPINRAZA has shown efficacy across ages and SMA types with a well-established safety profile based on data in patients treated up to 10 years, combined with unsurpassed real-world experience. The most common adverse events observed in clinical studies were respiratory infection, fever, constipation, headache, vomiting and back pain. Laboratory tests can monitor for renal toxicity and coagulation abnormalities, including acute severe low platelet counts, which have been observed after administration of some ASOs. Biogen licensed the global rights to develop, manufacture and commercialize SPINRAZA from Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). Please click here for Important Safety Information and full Prescribing Information for SPINRAZA in the U.S., or visit your respective country's product website. About Ionis Neurology Ionis has been at the forefront of discovering and developing leading neurological disease medicines, including SPINRAZA® (nusinersen), the first approved treatment for spinal muscular atrophy, WAINUA™ (eplontersen), a medicine to treat hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), and QALSODY® (tofersen) for SOD1-ALS. The clinical-stage portfolio includes 13 therapies, of which eight are wholly owned by Ionis. Ionis' investigational portfolio includes medicines for which there are few or no disease modifying treatments, such as rare diseases including Angelman syndrome, Prion disease and Alexander disease and more common conditions such as Alzheimer's and Parkinson's disease. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit and follow us on X (Twitter), LinkedIn and Instagram. Ionis Forward-looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of salanersen (ION306/BIIB115), our commercial medicines, additional medicines in development and technologies. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2024, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals® is a trademark of Ionis Pharmaceuticals, Inc. SPINRAZA® and QALSODY® are registered trademarks of Biogen. WAINUA™ is a registered trademark of the AstraZeneca group of companies. View source version on Contacts Ionis Investor Contact: D. Wade Walke, 760-603-2331 Ionis Media Contact: Hayley Soffermedia@ 760-603-4679 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data